EIC Vice Chair
Oregon State University
EIC Past Chair
Yale School of Public Health
Dr. Anthony Bahinski is Chief Technology Officer at Vivodyne, where he leads the translation of Vivodyne’s automated platform for massively scalable safety and efficacy testing on lifelike lab-grown human tissues to pharmaceutical and regulatory partners. Prior to joining Vivodyne, he served as the Global Head of Safety Pharmacology at GlaxoSmithKline. At GlaxoSmithKline, his responsibilities were focused on coordinating a global strategy to investigate safety risks of drugs on the cardiovascular, respiratory, CNS, renal, and other specialized tissues, both in vitro and in vivo. Dr. Bahinski’s career spans academic research and large Pharma, with more than 20 years’ experience in the pharmaceutical industry. He served as Lead Senior Staff Scientist on the Advanced Technology Team at Harvard’s Wyss Institute, leading DARPA and FDA collaborative efforts in development of organ chip systems. Dr. Bahinski has served on several advisory boards and is a current member of the Science Board of the US FDA, US EPA Board of Scientific Counselors (BOSC), and the Industrial Advisory Board for Dutch Research Council awarded SMART Organ on Chip (OoC) project. He is a member of the Editorial Board of the journals, Applied In Vitro Toxicology and Frontiers in Pharmacology of Ion Channels and Channelopathies. He has served on Peer Review Panels at the NIH, US EPA and NCI SBIR. Dr. Bahinski is author/co-author of over 40 publications including peer-reviewed articles and book chapters.
Sumitomo Dainippon Pharma Co., Ltd.
Environment and Climate Change Canada
Trinidad & Tobago Ministry of Health
Dr. Brown Jordan is from the Caribbean twin nation of Trinidad & Tobago (T&T). She was awarded a PhD in Veterinary Microbiology from the University of the West Indies, St. Augustine Campus in 2019, while her masters program at the London School of Hygiene and Tropical Medicine was in the field of Medical Microbiology. She was a past recipient of an Epigenesis Young Scientist Award for Animal Health in the Caribbean, a project initiative by the French Agricultural Research Centre for International Development (CIRAD). Her research areas of interest and background reside in laboratory diagnostics for both human and animal health pathogens of importance, with specific strengths in molecular biology and virology.
She has worked extensively with various governmental institutions in the area of laboratory strengthening due to her extensive knowledge in viral agents, emerging pathogens as well as modern laboratory and diagnostic sciences. Her knowledge and experiences have afforded her the opportunity to contribute more recently to the development of a new International Organization for Standards (ISO) standard document related to SARS-CoV-2 detection as well as to guide national establishment of molecular and antigen testing programs for SARS-CoV-2 in T&T.
Brown Jordan’s main propelling factors for being involved in research and scientific development, is her desire to see greater progress and strides towards the resolution of global challenges and going further towards implementation of the solutions, as evident by her pursuits. She is mother to and advocate for one special needs son and enjoys being a fashion creative when time is afforded.
US Food and Drug Administration
Dr. Suzanne Fitzpatrick is a board certified toxicologist here and in Europe and is an internationally recognized expert in alternative methods. She is the Senior Advisor for Toxicology at FDA/CFSAN. She is the FDA lead to ICCVAM and Tox 21 and chairs the FDA Alternative Methods Work Group. Dr. Fitzpatrick is the FDA representative to the International Regulatory Committee for the European Research Projects under ASPIS (Rik Hunter, ONTOX and Precision Tox) and she cochairs the EFSA and CFSAN Work Group on NAMS.
Public Health England
George Washington University
National Institute of Health Sciences, Japan
NIH National Heart, Lung, and Blood Institute
Dr. MacDonald Gibson is Professor and Department Chair in the Environmental and Occupational Health Department of the School of Public Health at Indiana University in Bloomington, IN. She earned two PhDs in 2007 in Engineering and Public Policy and Civil and Environmental Engineering at the Carnegie Mellon University in Pittsburgh, PA.
Her research addresses news stories of health risks from toxic waste spills, polluted water supplies, hazy air, contaminated foods, and other environmental problems abound. It also involves sorting through the headlines to figure out what environmental risks really might be important to our health or our community’s health and figuring out how to decrease those risks can seem an insurmountable task. She seeks to illuminate what individuals, communities, and policymakers can do to make the biggest and most lasting improvements in public health by improving the quality of our environment.
Her students and she parse complicated environmental problems into manageable elements that can be modeled mathematically and re-integrated to inform environmental and public health policy decisions. They have worked across the globe, from the US to the United Arab Emirates. Their work examines environmental risks to health at the scale of communities, building models that integrate knowledge of how pollutants are distributed through communities, how people become exposed to pollutants and other environmental risks factors, and how these exposures, in turn, increase risks of illness or premature death. Their main tools are drawn from applied mathematics and statistics, but they also conduct field research. Her students have collected and analyzed water and air samples, administered surveys, and conducted focus group interviews, in order to develop the knowledge needed to understand environmental risks to public health and advance policies to reduce those risks. Given an important environmental policy question, they find the tools needed to analyze potential solutions.
Misti Ushio is formerly the CEO of TARA Biosystems which was acquired by ValoHealth in 2022.
TARA Biosystems develops physiologically relevant 3D tissue models for drug discovery and development applications. The company’s Biowire™ II platform enables generation of large amounts of human relevant data for predictive drug development. TARA accelerates discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities, and also evaluates early cardiac risk assessment of drug discovery candidates.
Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she advised and invested in life science companies to help them translate their transformational science into commercially successful companies.
Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.
She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the boards of private and public life science companies. In 2018, she was named to Fast Company’s Top 100 Most Creative people in Business.